<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39241960</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1569-8041</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>04</Day></PubDate></JournalIssue><Title>Annals of oncology : official journal of the European Society for Medical Oncology</Title><ISOAbbreviation>Ann Oncol</ISOAbbreviation></Journal><ArticleTitle>A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0923-7534(24)03928-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.annonc.2024.08.2347</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This exploratory pooled analysis investigated the efficacy and safety of trastuzumab deruxtecan (T-DXd) versus comparator treatment in patients with HER2-positive metastatic breast cancer (mBC) with brain metastases (BMs) at baseline, categorized according to previous local treatment.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">T-DXd data were pooled from DESTINY-Breast01/-02/-03. Comparator data, from patients receiving physician's choice therapy and trastuzumab emtansine, were pooled from DESTINY-Breast02 and -03, respectively. Baseline BM status was assessed according to US Food and Drug Administration criteria. Endpoints included intracranial objective response rate (ORR; complete or partial response in brain) per blinded independent central review (BICR) by RECIST v1.1, time to intracranial response, intracranial duration of response (DoR), central nervous system progression-free survival (CNS-PFS) by BICR, overall survival (OS), and safety.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">148 patients who received T-DXd and 83 patients who received comparator treatment had BMs at baseline. In those who were treated with T-DXd, the intracranial ORR of patients with treated/stable and untreated/active BMs was 45.2% and 45.5%, respectively. The median (range) time to intracranial response was 2.8 months (1.1-13.9 months) and 1.5 months (1.2-13.7 months) in patients with treated/stable and untreated/active BMs, respectively. For those with treated/stable BMs, the median (95% CI) intracranial DoR was 12.3 months (9.1-17.9 months), and for those with untreated/active BMs it was 17.5 months (13.6-31.6 months). The median (95% CI) CNS-PFS and OS was 12.3 months (11.1-13.8 months) and not reached (22.1 months-not estimable [NE]) in those with treated/stable BMs, and 18.5 months (13.6-23.3 months) and 30.2 months (21.3 months-NE) in those with untreated/active BMs, respectively. Drug-related TEAEs grade ≥3 were experienced by 43.2% of patients with BMs and 46.4% without BMs with T-DXd.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">T-DXd demonstrated meaningful intracranial efficacy and clinical benefit in OS, with an acceptable and manageable safety profile in patients with HER2-positive mBC with treated/stable and untreated/active BMs.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>André</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Breast Cancer, Gustave Roussy, Villejuif, France. Electronic address: fabrice.andre@gustaveroussy.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cortés</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Medical Oncology, International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona, Spain; Scientific Department, Medica Scientia Innovation Research, Barcelona, Spain, and Ridgewood, New Jersey; Department of Medicine, Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain; IOB Madrid, Hospital Beata Maria Ana, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curigliano</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; Division of Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modi</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Tumor Center, The First Hospital of Jilin University, Changchun, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Y H</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>W-P</ForeName><Initials>WP</Initials><AffiliationInfo><Affiliation>Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>S-B</ForeName><Initials>SB</Initials><AffiliationInfo><Affiliation>Department of Oncology, Asan Medical Center, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamashita</LastName><ForeName>T</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrini</LastName><ForeName>J L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Mastologia, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Im</LastName><ForeName>S-A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tseng</LastName><ForeName>L-M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Department of Surgery, Taipei Veterans General Hospital, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harbeck</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center Munich, LMU University Hospital, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krop</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Yale Cancer Center, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nakatani</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Development, Daiichi Sankyo Co., Ltd., Tokyo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tecson</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Oncology Biostatistics, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashfaque</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Safety, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Egorov</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Oncology Research and Development, Daiichi Sankyo Inc., Basking Ridge, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurvitz</LastName><ForeName>S A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Division of Hematology and Oncology, University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Oncol</MedlineTA><NlmUniqueID>9007735</NlmUniqueID><ISSNLinking>0923-7534</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HER2+</Keyword><Keyword MajorTopicYN="N">brain metastases</Keyword><Keyword MajorTopicYN="N">intracranial</Keyword><Keyword MajorTopicYN="N">metastatic breast cancer</Keyword><Keyword MajorTopicYN="N">pooled analysis</Keyword><Keyword MajorTopicYN="N">trastuzumab deruxtecan</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>7</Day><Hour>14</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>7</Day><Hour>14</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>6</Day><Hour>19</Hour><Minute>24</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39241960</ArticleId><ArticleId IdType="doi">10.1016/j.annonc.2024.08.2347</ArticleId><ArticleId IdType="pii">S0923-7534(24)03928-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle>